Evidence map›Paper›PMID 40184428›Full record

ArticlePLoS pathogens2025

Intact HIV DNA decays in children with and without complete viral load suppression.

Daniel B Reeves, Morgan Litchford, Carolyn S Fish, Anna Farrell-Sherman, Makayla Poindexter, Nashwa Ahmed, Noah A J Cassidy, Jillian Neary, Dalton Wamalwa, Agnes Langat and 10 more

Abstract read
In one paragraph

Article in PLoS pathogens, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Long-Term Clinical, Immunologic, and Viral Reservoir Outcomes in Children Treated With VRC01LS and 10-1074 Monoclonal Antibodies in the Tatelo Study.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026
    Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Daniel B ReevesVaccine and Infectious Diseases, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America.ORCID 0000-0001-5684-9538
Morgan LitchfordHuman Biology, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America.
Carolyn S FishHuman Biology, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America.
Anna Farrell-ShermanVaccine and Infectious Diseases, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America.
Makayla PoindexterVaccine and Infectious Diseases, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America.
Nashwa AhmedVaccine and Infectious Diseases, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America.
Noah A J CassidyHuman Biology, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America.
Jillian NearyGlobal Health, University of Washington, Seattle, Washington, United States of America.
Dalton WamalwaGlobal Health, University of Washington, Seattle, Washington, United States of America.
Agnes LangatDepartment of Pediatrics and Child Health, University of Nairobi, Nairobi, Kenya.
Daisy ChebetDepartment of Pediatrics and Child Health, University of Nairobi, Nairobi, Kenya.
Hellen MoraaDepartment of Pediatrics and Child Health, University of Nairobi, Nairobi, Kenya.
Annukka A R AntarDepartment of Medicine, Johns Hopkins University, Baltimore, Maryland, United States of America.
Jennifer SlykerGlobal Health, University of Washington, Seattle, Washington, United States of America.
Sarah Benki-NugentGlobal Health, University of Washington, Seattle, Washington, United States of America.
Lillian B CohnVaccine and Infectious Diseases, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America.
Joshua T SchifferVaccine and Infectious Diseases, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America.
Julie OverbaughHuman Biology, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America.
Grace John-StewartGlobal Health, University of Washington, Seattle, Washington, United States of America.
Dara A LehmanGlobal Health, University of Washington, Seattle, Washington, United States of America.

Funding

University of Washington/Fred Hutch Center for AIDS ResearchP30AI027757 · NIAID · UNIVERSITY OF WASHINGTON · PI CONNIE L CELUM · 1988 to 2026
$104.9M
REACH: Research Enterprise to Advance a Cure for HIVUM1AI164565 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI Marina Caskey, R. Brad Jones · 2021 to 2026
$32.9M
Urgent Versus Post-Stabilization ART in HIV+ Children with Severe Co-infectionsR01HD023412 · NICHD · UNIVERSITY OF WASHINGTON · PI Grace C. John-Stewart, DALTON CHEKOKO WAMALWA · 1987 to 2026
$12.2M
Infant immune mechanisms of HIV reservoir size and decayR01HD094718 · NICHD · UNIVERSITY OF WASHINGTON · PI JOHN-STEWART, GRACE C., LEHMAN, DARA ANN · 2017 to 2021
$3.6M
Phylodynamic mechanisms of HIV reservoir seeding and maintenanceR01AI186721 · NIAID · FRED HUTCHINSON CANCER CENTER · PI Daniel Reeves · 2024 to 2026
$2.6M
Mathematical modeling of optimal therapeutic combinations for HIV cureR01AI150500 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI SCHIFFER, JOSHUA TISDELL · 2020 to 2024
$2.3M
Simulating persistence and elimination of the HIV reservoirK25AI155224 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI REEVES, DANIEL · 2020 to 2024
$581k
Deep sequencing of the HIV latent reservoir to discern mechanisms of clonal proliferation and HIV persistenceR21AI186783 · NIAID · JOHNS HOPKINS UNIVERSITY · PI ANTAR, ANNUKKA AIDA ROSE · 2024 to 2025
$447k
NIAID NIH HHS K25 AI155224NIAID NIH HHS P30 AI027757NIAID NIH HHS R01 AI150500NIAID NIH HHS R01 AI186721NIAID NIH HHS R21 AI186783NIAID NIH HHS UM1 AI164565NICHD NIH HHS R01 HD023412NICHD NIH HHS R01 HD094718
6 · The paper itself

Abstract

To inform cure in children living with HIV (CWH), we elucidated the dynamics and mechanisms underlying HIV persistence during antiretroviral therapy (ART). In 120 Kenyan CWH who initiated ART between 1-12 months of age, 55 had durable viral load suppression, and 65 experienced ART interruptions. We measured plasma HIV RNA levels, CD4+ T cell count, and levels of intact and defective HIV DNA proviruses via the cross-subtype intact proviral DNA assay (CS-IPDA). By modeling data from the durably suppressed subset, we found that during early ART (year 0-1 on ART), plasma RNA levels decayed rapidly and biphasically and intact and defective HIV DNA decayed with mean 3 and 9 month half-lives, respectively. After viral suppression was achieved (years 1-8 on ART), intact HIV DNA decay slowed to a mean 22 month half-life, whilst defective HIV DNA no longer decayed. In five CWH, we found individual CD4+ TCRβ clones wax and wane, but average kinetics resembled those of defective DNA and CD4 count, suggesting that differential decay of intact HIV DNA arises from selective pressures overlaying normal CD4+ T cell kinetics. Finally, by modeling HIV RNA and DNA in CWH with treatment interruptions, we linked temporary viremia to transient rises in HIV DNA, but long-term intact reservoirs were not strongly influenced, suggesting brief treatment interruptions may not significantly increase HIV reservoirs in children.

Indexed as

DNA, ViralHIV-1HIV InfectionsViral LoadAnti-HIV AgentsCD4 Lymphocyte CountCD4-Positive T-LymphocytesChildChild, PreschoolFemaleHumansInfantKenyaMaleProvirusesRNA, ViralAnti-HIV AgentsDNA, ViralRNA, Viral

Identifiers

PMID40184428
PMCPMC12002518

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.